• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·SNY
Held by 3 Gurus
Share

Sanofi Stocks

$ 41.18Last Updated 28.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 98.71B

$ 41.18
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.04%

Fund

Point72 Asset Management, L.P.

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.04%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%+0.04%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.04%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

24.07.2026 14:59

IPO Scribe: Shares in a biotech company backed by Eli Lilly and Sanofi are now available

23.06.2026 00:29

AbbVie will acquire a psoriasis drug developer for $11 billion. Its stock rose 47%.

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

24.12.2025 16:58

Sanofi is expanding its vaccine business. It will buy Dynavax for $2.2 billion

15.12.2025 19:23

Sanofi's stock is down. Its sclerosis drug suffers 'double blow'

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of SNY is 54.7 and suggests 32.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.09.2026 10:23

Top Stories This Morning: OpenAI Is Seeking $30 Billion; Trump Agrees on Industry Rules With AI Leaders

30.09.2026 08:00

Netflix shares are on track for their worst performance since 2022. Wall Street forecasts are mixed

30.09.2026 07:00

An analyst identified SpaceX's largest source of revenue. This could boost the stock by 30%

30.09.2026 05:07

OpenAI has released a suite of AI assistants called Dots. They are seen as a response to Meta's Muse agent.

30.09.2026 03:01

The market sharply scaled back expectations of a Fed rate hike in October following a key signal

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026